Alteration of Concanavalin A Binding Glycoproteins in Cerebrospinal Fluid and Serum of Alzheimer's Disease Patients by Hashimoto, Yuki et al.
1Yonago Acta medica 2008;51:1–9
Abbreviations:  AD, Alzheimer’s disease; Con A, concanavalin A; CSF, cerebrospinal fluid; DLB, dementia with Lewy 
bodies
Alteration of Concanavalin A Binding Glycoproteins in 
Cerebro spinal Fluid and Serum of Alzheimer’s Disease Patients
Yuki Hashimoto, Miyako Taniguchi, Miki Kitaura, Yuka Nakamura, Daiki Jimbo and 
Katsuya Urakami
 
Department of Biological Regulation, School of Health Science, Tottori University Faculty of Medi-
cine, Yonago 683-8503 Japan
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly.  It is char-
acterized pathologically by the formation of senile plaques and neurofibrilly tangles in the 
brain.  Diagnostic markers for detecting earlier stages of AD are needed.  We measured 
the intensity of concanavalin A (Con A) binding activities of glycoproteins of the cerebro-
spinal fluid (CSF) and serum of subjects to clarify the modification of core mannose since 
we expected that aberrant glycosylation of glycoproteins might be useful as a new bio-
marker for detecting AD.  CSF samples were collected from 15 patients with probable AD 
(AD group), 5 patients with probable dementia with Lewy bodies (DLB) (DLB group) and 
8 controls without dementia (control group), whereas serum samples from 20 patients with 
probable AD and 20 controls without dementia were also collected.  Glycoproteins in the 
CSF and serum were detected by lectin blotting using Con A.  In the CSF of the AD group, 
2 Con A binding glycoproteins were significantly higher compared with the control group. 
Furthermore, using analysis of variance, 3 Con A binding glycoproteins detected from 
the CSF of the AD group showed significant differences among the 3 groups.  The levels 
of 3 Con A binding glycoproteins were significantly lower than in non-dementia controls 
in the serum.  These changes in Con A binding activities did not depend on the amount of 
proteins.  Therefore, the data indicate that the aberrance of protein glycosylation relates to 
the pathology of AD, and has some promise as a new biomarker for the diagnosis of AD. 
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Alzheimer’s disease (AD) is an age-related demen-
tia characterised pathologically by the appearance 
of senile plaques composed primarily of aggregat-
ed forms of -amyloid protein and neurofibrillary 
tangles in the brain (Glenner and Wong, 1984; 
Grundke-Iqbal et al., 1986).  Since the 1990’s, AD 
has become the most common cause of dementia 
in Japan (Urakami et al., 1998).  AD is not only a 
medical care issue but also a social issue, because 
of the rapid aging of the population in Japan and 
other countries. 
 Recently, donepezil hydrochloride, an in-
hibitor of acetylcholinesterase, was created for 
the treatment of AD (Yamanishi et al., 1998).  It 
is used as a treatment for mild to moderate AD 
patients in Japan (Homma et al., 2000), and it’s ef-
fectiveness in mild cognitive impairment, which 
is the prodromal stage of AD, has been reported 
(Salloway et al., 2004).  Clinical diagnosis of AD 
is based on a clinical interview of the patient’s 
medical history, neuropsychiatric examinations and 
neuroimaging studies.  However, there is a matter 
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of objectivity in current diagnostic criteria for AD. 
Therefore, specific biological diagnostic markers 
for detecting earlier stage of AD and specific dis-
tinction of AD are becoming more important. 
 The need to improve diagnostic accuracy 
has prompted the search for diagnostic markers in 
the cerebrospinal fluid (CSF) or serum of persons 
with AD.  To date, no single biochemical marker 
has been found to yield sufficient sensitivity and/
or specificity of detection.  Nevertheless, the com-
bination of multiple biomarkers such as tau, -am-
yloid 1-42 and -40 (Galasko et al., 1998; Kanai et 
al., 1998) may improve diagnostic accuracy.  Ad-
ditionally, there are new possibile biomarkers for 
the diagnosis of AD such as apolipoprotein A-1, 
cathepsin D, hemopexin, transthyretin and 2 pig-
ment epithelium-derived factor isoforms (Abdi et 
al., 2006; Castano et al., 2006).  Identification of 
new biological markers, which can be used alone, 
or in combination with other markers is highly 
necessary. 
 Among the more than 100 types of post-
translational modifications, glycosylation is the 
most common.  N-type glycosylation on as-
paragines and O-type glycosylation on serine or 
threonine occur in over 50% of all proteins (Varki 
et al., 1999).  Altered glycosylation is reported 
in several disease states (Lis and Sharon, 1986; 
Collinge et al., 1996) and in AD (Ahmed and 
Thornalley, 2002).  Glycosylation of proteins with 
glucose and other saccharide derivatives leads to 
the formation of fructosamines and advanced gly-
cation endproducts (Day et al., 1979; Furth, 1988). 
Formation of the endproducts has been linked 
to the development of AD (Dukic-Stefanovic et 
al., 2001).  Additionally, neural sialyltransferase, 
which catalyses the addition of terminal sialic 
acid onto newly synthesized proteins following 
removal of core mannose sugars (Paulson and 
Colley, 1989; Harduin-Lepers et al., 1995), is de-
creased in the brains of AD patients (Maguire and 
Breen, 1995). 
 Lectins are powerful tools for distinguish-
ing differences in the carbohydrate composition 
of glycoproteins (Lis and Sharon, 1986; Elgavish 
and Shaanan, 1997). Concanavalin A (Con A) is 
one of the lectins that targets the core mannose 
(Ohyama et al., 1985).  We examined the altera-
tion of core mannose modification by measuring 
Con A binding activities of glycoproteins in the 
CSF and serum.  In this study, we showed the 
difference in glycosylation between the CSF and 




Before collecting samples, informed consent was 
obtained from the patients and their families, and 
ethical investigation was approved.  All subjects 
were examined by a dementia specialist (KU). 
Then, interviews of medical history, neuropsy-
chiatric examinations and neuroimaging studies, 
such as computed tomography and/or magnetic 
resonance imaging, single photon emission com-
puted tomography were carried out for the diag-
nosis.  AD diagnosis was done according to the 
Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition (American Psychiatric As-
sociation, 1994) and the National Institute of Neu-
rological Communicative Disorders and Stroke 
and the Alzheimer Disease and Related Disorders 
Association Criteria (McKhann et al., 1984).  De-
mentia with Lewy bodies (DLB) is characterized 
by persistent visual hallucinations, fluctuating 
cognitive impairment and parkinsonisms, and 
typical senile dementia.  The diagnosis for DLB 
patients was done using the diagnosis in the con-
sensus guidelines for the clinical and pathologic 
diagnosis of DLB (McKeith, 2006).  Non-demen-
tia control subjects had no cognitive impairments 
or diseases of the nervous system, yet may have 
had some other diseases not related to dementia. 
All samples were immediately frozen immedi-
ately after collecting  until experimentation. 
 CSF samples were collected from 15 patients 
with probable AD, 5 patients with probable DLB and 
8 non-dementia controls (Table 1).  The AD group 
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consisted of 8 males and 7 females (mean age ± SD, 
73.8 ± 5.2 years), the DLB group, 3 males and 2 
females (77.2 ± 3.4 years) and the control group, 3 
males and 5 females (73.3 ± 8.5 years). 
 Serum samples were collected from 20 prob-
able AD patients and 20 non-dementia controls 
(Table 2). The AD group was made of 7 males 
and 13 females (79.2 ± 6.8 years), and the control 
group, 4 males and 16 females (71.6 ± 12.0 years). 
This study did not use the same subject sample 
between the CSF and serum. 
 
Pretreatment of samples
The quantity of total protein included in the CSF 
and serum were determined by absorptiometry 
using Protein Assay Kit II (Bio-Rad, Hercules, 
CA), and albumin was eliminated by a Montage 
Albumin Deplete Kit (Millipore, Billerica, MA). 




We applied the technique of lectin blotting (Savage 
et al., 1992) for detection of Con A binding gly-
coproteins.  Each sample containing total protein 
of 5 μg was mixed with a sample buffer to a final 
concentration of 12 mM Tris-HCl (pH 6.8), 25% 
glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol 
and 0.1% bromophenol blue, and boiled in a boil-
ing bath for 5 min.  The mixtures and molecular 
weight markers (GE Healthcare, Buckingham-
shire, United Kingdom) were separated by 5% 
to 20% SDS-PAGE in a running buffer (pH 8.3) 
containing 25 mM Tris, 192 mM glycine and 
0.1% SDS.  SDS-PAGE was performed by 20 
mA/56 cm2 (area) and 1 mm (thickness) for 90 
min.  Separated proteins were electrophoreti-
cally transferred onto a polyvinylidene difluoride 
membrane (Millipore) previously activated into 
a transfer buffer containing 16 mM Tris, 120 
mM glycine and 10% methanol at 100 mA for 1 
h.  The membrane was blocked in a Block Ace 
Solution (Dainippon Sumitomo Pharma, Osaka, 
Table 1.  Characteristics of CSF samples 
 Gender  
     Group (M/F)   Age* Status
AD [15] 8/7 73.8 ± 5.2  Probable
DLB  [ 5] 3/2 77.2 ± 3.4 Probable
Control  [ 8] 3/5 73.3 ± 8.5 No cognitive impairments 
and diseases of the NS
 [  ], number of subjects.
* Mean ± SD. 
 AD, Alzheimer’s disease; CSF, cerebrospinal fluid; DLB, 
dementia with Lewy bodies; F, female; M, male; NS, ner-
vous system.
Table 2.  Characteristics of serum samples 
 Gender  
     Group (M/F)   Age* Status
AD  [20] 7/13 79.2 ± 6.8  Probable
Control  [20] 4/16 71.6 ± 12.0 No cognitive impairments 
and diseases of the NS
 [  ], number of subjects.
* Mean ± SD. 
 AD, Alzheimer’s disease; F, female; M, male; NS, nervous 
system.
Japan) for 1 h at room temperature with shaking. 
The blocked membranes were then rinsed with 
0.1% Tween-20 in phosphate-buffered saline, and 
each was washed 3 times for 5 min with shaking 
at room temperature.  Then, the membranes were 
incubated with 2 μg/mL Con A labeled biotin (J-
Oil Mills, Tokyo, Japan) overnight at 4˚C.  Final-
ly, biotinylated Con A binding glycoproteins were 
reacted with Streptavidin-Conjugated Alkaline 
Phosphatase (1:1000 dilution) (Promega, Madison, 
WI) for 2 h at 25˚C and visualized with Western 
Blue (Promega).  The Con A binding activities of 
each band were analyzed by Multi Gauge version 
2.1 software (Fuji Film, Tokyo).  The difference 
of staining of each membrane was compensated 
by the background intensity of area took from the 
original intensity of glycoprotein band.
 
Coomassie brilliant blue staining
Every protein in the SDS-PAGE gel was stained 
with coomassie brilliant blue solution containing 




We detected some Con A binding glycoproteins in 
the CSF by lectin blotting, and tentatively named 
them a (over 250 kDa) to g (about 25 kDa) in de-
scending order of molecular weight (Fig. 1).  Con 
A binding activities of the 4 glycoproteins in the 
CSF are shown in Fig. 2. 
 Figures 2-I to -IV indicate intensities of Con 
A binding activities of CSF glycoproteins.  The 
levels of Con A binding activities of glycoproteins 
a (6,477 ± 2,520) (mean ± SD) and g (9,650 ± 
5,557) from the CSF in the AD group were signif-
icantly higher than those of a (3,978 ± 2,133) and 
g (4,779 ± 1,746) in the control group (P < 0.05). 
Con A binding glycoprotein a had 88.89% sensi-
tivity and 66.67% specificity (cut off 5026) and g 
had 77.78% sensitivity and 73.77% specificity (cut 
off 5783) between the AD group and the control 
group.  Additionally, the Con A binding activity 
of glycoprotein b (between 250 and 160 kDa) in 
the AD group was also higher than that of the 
DLB group (P < 0.05) and that had 100.0% sen-
sitivity and 66.67% specificity (cut off 7303) be-
tween those 2 groups, but there was no significant 
difference between the AD and control groups. 
The intensity of f (between 35 and 30 kDa) and g 
in the DLB group were significantly higher than 
in the control group (P < 0.01) and those Con A 
binding glycoproteins had 100.0% sensitivity and 
100.0% specificity (cut off 8010: f, 9503: g).  The 
intensities of CSF Con A binding glycoprotein b, 
f and g had significant difference among 3 groups 
(P < 0.05, analysis of variance). 
 We performed lectin blotting of Con A bind-
ing glycoproteins in the serum, and called A 
(between 250 and 160 kDa) to J (about 25 kDa) 
in descending order of molecular weight (Fig. 3). 
Figure 4 shows intensities of Con A binding ac-
tivities of glycoproteins in the serum.  In the AD 
group, the Con A binding intensity of glycopro-
tein H (between 50 and 35 kDa) (6,234 ± 2,692), 
50% methanol, 0.5 mg/mL coomassie brilliant 
blue and 10% acetic acid for 20 min at room tem-
perature with shaking.  Also, the gel had its color 
removed with 25% ethanol and 8% acetic acid at 
room temperature with shaking until positive pro-
tein bands appeared.  
 
Silver staining
The amount of CSF protein was lower than the 
serum protein, and the sensitivity of protein detec-
tion in coomassie brilliant blue staining was lower 
than that of silver staining.  We could not visual-
ize the protein of CSF in coomassie brilliant blue 
staining, and so we performed silver staining of 
the protein in the gel.  The gel was swamped into 
50% methanol for 10 min at room temperature 
with shaking then washed with distilled water for 
10 min at room temperature.  Sodium thiosulfate 
(0.02%) was used for intensifying the reaction for 
3 min, followed by incubation with silver nitrate 
solution containing 1 mg/mL silver nitrate in 
0.34% sodium hydroxide and 1.7% ammonia for 
20 min at room temperature with shaking.  Then, 
each gel was washed 4 times with distilled water 
for 10 min at room temperature, and developed 
with 2% sodium carbonate in 0.004% formalde-
hyde at room temperature with shaking.  To stop 
the reaction, 7% acetic acid solution was used for 
10 min at room temperature. 
Statistical analysis and receiver operating 
characteristic analysis
Intensities of Con A binding activities of glycopro-
teins were compared with Mann-Whitney’s U-test: 
among the AD, the DLB and control groups for 
the CSF;  and between the AD and control groups 
for the serum.  We also compared the levels of 
CSF Con A binding glycoproteins among the 3 
groups with analysis of variance.  Con A binding 
glycoproteins which showed significant differ-
ences by statistical analysis in the CSF and serum 
were analyzed by receiver operating characteristic 
analysis for indicating sensitivity and specificity.  
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Fig. 1.  Banding patterns of concanavalin A (Con A) reactive glycoproteins in the cerebrospinal fluid (CSF) detected 
by lectin blotting with Con A.  Glycoproteins analyzed in this study (black arrow heads) are tentatively named a to g. 
Lane M: molecular markers; AD, Alzheimer’s disease patients; control, non-dementia control subjects.
Fig. 2.  Concanavalin A (Con A) binding activities of the cerebrospinal fluid (CSF) glycoprotein a, b, f and g deter-
mined by densitometry are seen in 2-I, -II, -III and IV, respectively.  Shown are intensities of each samples.  *P < 0.05, 
**P < 0.01:  comparison between the Alzheimer’s disease (AD) group and the dementia with Lewy bodies (DLB) 
group or control group, or both (Mann-Whitney’s U-test).  [  ], number of subjects.
I (about 30 kDa) (5,765 ± 2,290) and J (about 25 
kDa) (5291 ± 2089) were significantly lower than 
the control group:  8,851 ± 3,470 (P < 0.05), 8,817 
± 2,581 (P < 0.001), 7,564 ± 2,235 (P < 0.01), 
respectively.  Additionally, Con A binding glyco-
proteins H, I and J had 70.00% sensitivity and 
60.00% specificity (cut off 6454), 80.00% sensi-
tivity and 75.00% specificity (cut off 6311) and 
85.00% sensitivity and 65.00% specificity (cut off 
5657).  Other Con A binding glycoproteins had 
no significant differences between AD and other 
groups (data not shown). 
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Semiquantification of glycoproteins in the 
CSF and serum
We also analyzed protein levels of CSF and serum 
glycoproteins which showed significant intergroup 
differences with lectin blotting.  As proteins can 
be stained directly with coomassie brilliant blue 
or silver staining, we could compare the amount 
of glycoprotein.  Differences in protein levels of 
CSF Con A binding glycoproteins a, b, f and g 
were not significant between groups which had 
significant differences in Con A binding activi-
ties.  Differences in the amount of coomasie bril-
liant blue-stained serum glycoproteins H, I and J 





In AD patients, some Con A binding glycopro-
teins were altered in the CSF and serum.  These 
data indicate that the CSF Con A binding glyco-
proteins in a and g show the separation between 
the AD group and the control group.  However, in 
both CSF and serum, glycoproteins with different 
Con A binding activities were not distinguished 
by the amount.  From this we figured that the al-
Fig. 3.  Banding patterns of concanavalin A (Con A) reactive glycoproteins in the serum detected by lectin 
blotting with Con A.  Glycoproteins analyzed in this study (black arrow heads) are tentatively named A to J. 
Lane M: molecular markers; AD, Alzheimer’s disease patients; control, non-dementia control subjects.
Fig. 4.  Concanavalin A (Con A) binding activities of 
serum glycoproteins H, I and J determined by densitom-
etry are seen in 4-I, -II and -III respectively.  Shown are 
intensities of each samples. *P < 0.05, **P < 0.01, ***P 
< 0.001:  comparison between the Alzheimer’s disease 
(AD) group and control group (Mann-Whitney’s U-test). 
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teration was due to a sugar chain rather than to the 
amount of glycoprotein.  Additionally, the altera-
tion of the sugar chain specifically occurring at the 
mannose site was the reason for using Con A lec-
tin in this study.  Recently, there have been some 
reports which suggest the relationship between 
glycosylation and AD.  An unusual glycoform of 
acetylcholinesterase, which does not bind to Con A, 
is increased in the AD brain and CSF (Sáez-Valero 
et al., 1999, 2000).  Wheat germ agglutinin-bind-
ing glycoproteins are decreased in the CSF of AD 
patients (Fodero et al., 2001), and there is a rela-
tionship between aberrant glycosylation and the 
pathology of AD (Ahmed and Thornalley, 2002), 
while several glycoproteins are altered in AD 
(Puchades et al., 2003).  These results support our 
findings and suggest that a sugar chain of glyco-
proteins is altered in AD.  Moreover, it was possi-
ble to distinguish glycoproteins f and g in the DLB 
group from the control group. The glycoprotein b 
in the CSF might be separated the AD group from 
the DLB group.  The CSF glycoproteins b, f and 
g indicated aberrant glycosylation also occur in 
DLB, and this fact suggests that alteration of man-
nose glycosylation of Con A binding glycoprotein 
might be a new biomarker in not only AD but also 
other dementia such as DLB.
 On the other hand, we found that there was 
no significant difference in CSF glycoprotein d 
using lectin blotting with Con A in this study, 
although wheat germ agglutinin-binding activ-
ity was significantly lower than in the AD group 
in previous study (data not shown).  Wheat germ 
agglutinin specifically binds to -N-acetylglu-
cosamine and terminal sialic acid (Nagata and 
Burger, 1974; Monsigny et al., 1980).  These 
results suggested aberrances in glycosylation at 
-N-acetylglucosamine and/or sialic acid sites, 
but not at the mannose site.  In this way, using 
some lectins in the same glycoprotein might be 
able to clarify the site of altered sugar chain. 
 In AD, aberrant glycosylation of glycopro-
teins was found ubiquitously in the CSF, but those 
found in the serum were limited to the glycopro-
teins with relatively smaller molecular weights. 
Various molecular weights of Con A binding 
glycoproteins from the CSF such as a, b, f and g 
were found to have the potential of an aberrant 
sugar chain.  The change was found in Con A 
binding glycoproteins with both large and small 
molecular weights in the AD group and/or DLB 
group but not in the control group in the CSF, 
which is probably caused by a variation in glyco-
sylation.  However, altered Con A binding activi-
ties of serum glycoproteins were observed in gly-
coproteins with less than 40 kDa.  In the serum of 
AD patients, aberrant glycosylation suggested by 
Con A binding activity was limited to the glyco-
proteins with smaller molecular weights. 
 The central nervous system is isolated from 
the blood circulation by the blood-brain barrier 
and blood-cerebrospinal fluid barrier because of 
its physiological importance.  These barriers have 
been thought to protect the brain from various 
harmful materials in the circulation as static walls 
(Segal, 2000; Begley and Brightman, 2003; Nitta 
et al., 2003).  In addition, membrane proteins 
promote cell membrane permeability of a low 
molecular weight compound, called a transporter, 
and these membrane proteins have been thought 
to relate to the active efflux of harmful materials 
from the brain (Kusuhara and Sugiyama, 2001; 
Lee et al., 2001; Sun et al., 2003; Begley, 2004). 
Therefore, we considered that aberrant glycosyl-
ation of glycoproteins with a relatively large mo-
lecular weight which was directly or secondarily 
generated could not be excreted into the circu-
lating blood because of the blood-brain barrier 
and/or blood-cerebrospinal fluid barrier:  these 
glycoproteins might have been excreted into other 
metabolic pathways instead of those.  On the 
other hand, relatively smaller glycoproteins could 
be passed through the blood-brain barrier and/or 
blood-cerebrospinal fluid barrier into the circulat-
ing blood.  Consequently, a metabolic pathway us-
ing blood flow might exist for those glycoproteins 
as one possible pathway. 
 In the future, it will be necessary to identify 
the glycoproteins altered in AD.  However, we 
found that glycosylation of Con A binding gly-
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coproteins in the AD group was different in both 
CSF and serum.  Alteration of Con A binding ac-
tivities might especially have some use as a new 
biomarker in the serum.  On the other hand, this 
study has some difficult issues such as increasing 
of respective samples, identification of molecular 
weight of each Con A binding glycoprotein and 
investigation of DLB or other non-AD dementia in 
the serum.  In the immediate future, those prob-
lems will be solved and clarifying the mechanism 
of variant glycosylation in AD might contribute 
not only to the discovery of a new biomarker but 
also to the resolution of a new pathology. 
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